

RECEIVED

SEP 16 2002

TECH CENTER 1600/2900

#14 Q  
9-18-02  
P.2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION OF

Robert Lanza et al.

Application No. 09/655,815

Filed: September 6, 2000

Title: METHOD FOR GENERATING IMMUNE-COMPATIBLE CELLS AND TISSUES USING  
NUCLEAR TRANSFER TECHNIQUES



Group Art Unit: 1632

Examiner: T. Ton

\* \* \* \* \*

AMENDMENT AND REPLY

Hon. Commissioner of Patents  
Washington, D.C. 20231

Sir:

This Reply is responsive to the Office Action dated April 10, 2002. Kindly enter the following amendment and remarks prior to further examination.

A substitute specification is provided herewith. The substitute specification has a wider top margin than the originally filed specification, and the data table in Example 2 of the substitute specification is re-formatted so that it does not extend into the right margin. The text of the substitute specification is the same as that of the originally filed specification.

IN THE SPECIFICATION:

The paragraph beginning on line 30 of page 4 (line 1 of page 5 of the substitute specification) is amended as follows:

-- Thus, mitochondrial peptides displayed at the cell surface can serve as histocompatibility antigens, seeing as two separate systems have been identified in mice and rats, respectively. There is no reason to believe that similar systems would not be present in other mammals. Therefore, foreign mitochondria would be expected to result in the rejection of therapeutic tissue generated by nuclear transfer technology. Instead, using the methods of the present invention, the present inventors have surprisingly found in performing the